

CONTENTS

Foreword	xix
Preface	xx
Acknowledgments	xxi
Contributors	xxii
The COVID-19 Pandemic	xxv

Chapter 1 INTERNAL MEDICINE IN THE 21ST CENTURY—BEST PRACTICE, BEST OUTCOMES 1

*Brad Frankum, Simon O'Connor and
Nicholas J Talley*

General versus sub-specialty medicine	1
The importance of diagnosis	2
The physician's role in public health	2
The physician as scholar	2

Chapter 2 EVIDENCE-BASED MEDICINE AND CRITICAL APPRAISAL OF THE LITERATURE 5

Jane Young and John Attia

Introduction	5
Assessing the evidence	5
<i>Sources of error</i>	5
<i>Assessing potential biases in different study designs</i>	6
Critical appraisal of the literature	8
Interpreting a study's findings	9
Interpreting statistical analysis	10
Interpreting test results	11
Screening	13
Conclusion	13
Acknowledgments	13
Self-assessment questions	14

Chapter 3 CLINICAL PHARMACOLOGY AND TOXICOLOGY 17

Matt Doogue, Jennifer Martin and Alison Jones

1. PRINCIPLES OF CLINICAL PHARMACOLOGY 18	
Introduction	18
Pharmacokinetics	19
<i>Administration</i>	19

<i>Bioavailability (F)</i>	19
<i>Clearance (CL)</i>	19
<i>Distribution</i>	21
<i>Drug transport</i>	21
<i>Other pharmacokinetics</i>	22
<i>Altered pharmacokinetics</i>	22
<i>Patient size</i>	23
Pharmacodynamics	24
<i>Concentration–response relationships</i>	24
<i>Therapeutic index</i>	24
<i>Drug targets</i>	25
<i>Physiological effects</i>	26
<i>More about the patient</i>	26
The innocent bystander	26
2. QUALITY USE OF MEDICINES 26	
Getting it right	27
<i>The circle of care</i>	27
<i>Patient profile and drug profile(s)</i>	27
Prescribing	27
<i>The prescribing checklist</i>	28
Deprescribing	28
Adverse drug reactions	28
Drug interactions	29
<i>Types of drug interaction</i>	29
Therapeutic drug monitoring (TDM)	30
Drug regulation	30
Drug research	31
3. TOXICOLOGY 32	
Epidemiology of poisoning	32
Sources of poisons information and advice	32
Clinical assessment of poisoned patients	32
<i>Investigations</i>	32
<i>Risk assessment</i>	33
Principles of management of poisoned patients	33
Common poisons and their management	34
<i>Acetaminophen (paracetamol)</i>	34
<i>Non-steroidal anti-inflammatory drugs (NSAIDs)</i>	36
<i>Tricyclic antidepressants</i>	36
<i>Newer antidepressants</i>	36
<i>Second generation antipsychotics</i>	37
<i>Benzodiazepines</i>	37
<i>Insulin and oral hypoglycemics</i>	37
Drugs of abuse or misuse	38
<i>Amphetamines</i>	38
<i>Cocaine and crack cocaine</i>	38
<i>Gammahydroxybutyrate (GHB)</i>	38

<i>Opioids, such as heroin, morphine or fentanyl</i>	39	<i>Lines, tubes and implants</i>	66
<i>Prescription drug abuse</i>	39	<i>Anatomical review</i>	66
<i>Synthetic cathinones, e.g. 'vanilla sky', 'ivory wave'</i>	39	<i>Review areas ('hard to see areas')</i>	67
<i>Synthetic cannabinoids, e.g. 'spice', 'K2'</i>	39	<i>Summary</i>	67
<i>Drink spiking</i>	39	2. THORACIC COMPUTED TOMOGRAPHY	72
Chemicals	39	Techniques of examination	72
<i>Acids and alkalis</i>	39	Principles of interpretation in chest CT	72
<i>Chlorine</i>	40	<i>Patient demographics</i>	74
<i>Pesticides</i>	40	<i>Technical review</i>	74
<i>Lead poisoning</i>	40	<i>Initial image review</i>	74
Spider bites	40	<i>Key image review</i>	75
Snake bites	40	<i>Systematic review</i>	76
Marine envenomation	41	<i>Review areas</i>	76
Terrorism, and use of medical countermeasures	41	<i>Summary</i>	76
<i>Chemical agents</i>	41	3. ABDOMINAL COMPUTED TOMOGRAPHY	77
<i>Biological agents</i>	41	Techniques of examination	77
<i>Self-assessment questions</i>	44	<i>Non-contrast CT abdomen</i>	78
		<i>Non-contrast CT KUB</i>	78
		<i>Arterial phase CT abdomen</i>	
		<i>(CT angiogram, CTA)</i>	78
		<i>Portal venous CT abdomen</i>	78
		<i>Triple-phase CT abdomen</i>	78
		<i>Delayed CT abdomen</i>	78
		Principles of interpretation in abdominal CT	78
		<i>Patient demographics</i>	78
		<i>Technical review</i>	78
		<i>Initial image review</i>	79
		<i>Key image review</i>	79
		<i>Systematic review</i>	82
		<i>Review areas</i>	82
		<i>Summary</i>	82
		4. ABDOMINAL ULTRASOUND	82
		Background—ultrasound principles	82
		Principles of ultrasound interpretation	83
		Lower limb duplex ultrasound	85
		5. HEAD COMPUTED TOMOGRAPHY	86
		CT brain protocols	86
		<i>Non-contrast (NCCT)</i>	86
		<i>Contrast-enhanced (CECT)</i>	86
		<i>CT angiography (CTA)</i>	86
		<i>Perfusion CT</i>	87
		Principles of interpretation in brain CT	87
		<i>Patient demographics</i>	88
		<i>Technical review</i>	88
		<i>Initial image review</i>	88
		<i>Key image review</i>	90
		<i>Systematic review</i>	93
		<i>Review areas</i>	93
		<i>Summary</i>	93
		6. HEAD MAGNETIC RESONANCE	93
		MRI protocols	94
		<i>T1</i>	94
		<i>T2</i>	94
		<i>Inversion recovery (IR)</i>	95
		<i>Diffusion-weighted imaging (DWI)</i>	95
		<i>Gradient echo (GRE)</i>	98
		<i>Gadolinium-enhanced (GAD)</i>	98
		<i>Magnetic resonance angiography/venography</i>	
		<i>(MRA, MRV)</i>	99
Chapter 4			
GENETICS	47		
<i>John Attia and Tracy Dudding-Byth</i>			
Overview	47		
The flow of genetic information	48		
<i>Transcription</i>	48		
<i>Translation</i>	49		
<i>Regulation</i>	50		
Genetic variation	51		
Human disease genes	52		
Mendelian diseases	52		
Breast cancer predisposition genes	53		
Breast and ovarian cancer predisposition genes	53		
Calculating the risks of disease	53		
<i>Some examples</i>	53		
Genetic testing in medicine	55		
<i>Cytogenic karyotype</i>	55		
<i>Fluorescence in situ hybridization (FISH)</i>	55		
<i>Chromosomal microarray (molecular karyotype)</i>	56		
<i>Genome-wide association studies</i>	56		
<i>Polymerase chain reaction (PCR)</i>	56		
<i>Sequencing</i>	56		
<i>Mitochondrial DNA</i>	57		
<i>Imprinting</i>	57		
Common chromosomal genetic conditions	57		
<i>Down syndrome</i>	57		
<i>Turner syndrome</i>	57		
<i>Klinefelter syndrome</i>	57		
Acknowledgments	57		
<i>Self-assessment questions</i>	58		
Chapter 5			
MEDICAL IMAGING FOR INTERNISTS	63		
<i>Lindsay Rowe</i>			
1. CHEST RADIOGRAPHY	64		
Principles of interpretation in chest X-rays	64		
<i>Patient demographics</i>	64		
<i>Technical assessment</i>	64		

MR spectroscopy (MRS)	99
Magnetic resonance gated intracranial cerebrospinal dynamics (MR-GILD, CSF flow study)	99
Principles of interpretation in brain MR	99
Patient demographics	99
Technical review	99
Initial image review	99
Key image review	100
Systematic review	103
Review areas	103
Summary	103
7. POSITRON EMISSION TOMOGRAPHY (PET)	103

Chapter 6

PULMONOLOGY 105

David Arnold, Peter Wark, Michael Hensley,

Brad Frankum and Lucy Morgan

1. PULMONARY MEDICINE 106

Clinical presentations of respiratory disease	106
Important clinical clues	106
Dyspnea	106
Patterns of breathing	107
Chronic cough	108
Clubbing	108
Hemoptysis	108
Solitary pulmonary nodule (coin lesion)	109
Mediastinal masses	109
Wheeze	109
Chest pain	109
Stridor	110
Overview of the respiratory system and pathophysiology	110
Functional anatomy and physiology	110
Hypoxemia	111
Hypercapnia	111
Oxygen–hemoglobin association–dissociation curve	112
Acid–base disturbances from a pulmonary perspective	112
Respiratory acidosis	112
Respiratory alkalosis	112
Measurement of lung function	112
Spirometry	112
Interpretation of lung volumes	114
Diffusing capacity for carbon monoxide (DLCO test)	114
Flow–volume loops	114
Interpretation of pulmonary function tests	114
Control of breathing	114
Respiratory tract defenses	114
Mechanical defenses	114
Immune system	115
Genetics of lung disease	116
Pulmonary disorders	116
Respiratory failure	116
Hypoventilation	116
Diseases of the airways	116

Asthma	116
Allergic bronchopulmonary aspergillosis (ABPA)	118
Bronchiectasis	118
Cystic fibrosis (CF)	119
Bronchiolitis	119
Chronic obstructive pulmonary disease (COPD)	121
Interstitial lung disease (ILD)	122
Idiopathic pulmonary fibrosis	124
Occupational lung disease	124
Granulomatous ILD	126
Eosinophilic pulmonary disorders	127
Pulmonary hemorrhage	127
Pulmonary infections	127
Bacterial	127
Viral	128
Fungal	128
Mycobacterial	129
Other aspects	130
Pleural disease	132
Pleural effusion	132
Pneumothorax	132
Indications for a chest drain	132
Pulmonary vascular disease	132
Pulmonary hypertension (PH)	132
Pulmonary embolism (PE)	133
Diagnosis	133
Lung transplantation	134
Complications of lung transplantation	134
Respiratory sleep medicine	135
Overview of sleep medicine	135
Important clinical clues	135
Respiratory sleep disorders	135
2. CRITICAL CARE MEDICINE	137
Resuscitation	137
Cardiac arrest (CA)	137
Diagnosis and disease management	137
Shock	137
Acute respiratory distress syndrome (ARDS)	137
Mechanical ventilation of the lungs	139
Non-invasive positive-pressure ventilation (NIV)	140
Invasive positive-pressure ventilation (IPPV)	140
Extracorporeal membrane oxygenation (ECMO)	141
Self-assessment questions	142

Chapter 7

CARDIOLOGY 145

Peter Thompson

Clinical evaluation of the patient	146
<i>Taking the history—possible cardiac symptoms</i>	146
<i>Physical examination</i>	148
Investigation of cardiac disease	152
<i>Electrocardiography (EKG)</i>	152
<i>Holter (continuous EKG) monitoring</i>	152
<i>Ambulatory blood pressure monitoring</i>	152

Radionuclide ventriculography	155	Conduction defects	195
Chest X-ray (CXR)	155	Bundle branch block (BBB)	195
Echocardiography	155	Fascicular blocks (hemiblocks)	196
Radionuclide myocardial perfusion imaging	158	Atrioventricular (AV) blocks	196
Coronary angiography and cardiac catheterization	158	Cardiac failure	197
Coronary CT angiography (CTCA, CCTA) and calcium scoring	159	Definition	197
Magnetic resonance imaging (MRI)	160	Causes	197
Dyslipidemia	160	Diagnosis of congestive heart failure	197
Cholesterol, lipoproteins, apoproteins	161	Treatment	199
Dyslipidemia and cardiovascular disease (CVD)	162	Devices	201
Lipid-modifying treatments	164	Infective endocarditis	202
Coronary artery disease (CAD)	164	Microbiology	202
Prevalence	164	Diagnosis	203
Pathophysiology	164	Management	203
Stable coronary artery disease	165	Prevention	204
Investigation	165	Pericardial diseases	204
Management to improve prognosis	167	Acute pericarditis	204
Management of symptoms in the CHD patient	168	Pericardial effusion and tamponade	206
Management of refractory angina	169	Chronic pericardial disease	207
Acute coronary syndromes	169	Self-assessment questions	208
Terminology	169	Chapter 8	
Pathophysiology of acute coronary syndromes	170	HYPERTENSION	211
Management of STEMI	172	<i>Annemarie Hennessy and Simon O'Connor</i>	
Management of NSTEMI/Unstable Angina	173	Mechanisms of hypertension	211
Pharmacological therapy in acute coronary syndromes	174	Epidemiological evidence for hypertension and its effects	212
Valvular heart disease	174	Definitions of hypertension	214
Mitral valve disease	175	Clinical presentations and investigations	216
Mitral stenosis (MS)	175	Target-organ effects of hypertension	216
Mitral regurgitation (MR)	176	Blood vessels	216
Mitral valve prolapse (MVP) syndrome	178	Cardiac effects	217
Aortic valve disease	178	Retinopathy	217
Aortic stenosis (AS)	178	Renal changes secondary to hypertension	218
Aortic regurgitation (AR)	180	Brain	218
Tricuspid valve disease	181	Treatment and targets for hypertension control	218
Tricuspid stenosis (TS)	181	Specific targets linked to comorbid conditions	219
Tricuspid regurgitation (TR)	182	Treatment for chronic primary hypertension	219
Pulmonary valve disease	182	Optimal or normal adult	219
Assessing the severity of valvular heart disease and deciding on surgery	182	High-normal	220
Cardiomyopathies	182	Stage 1 hypertension	220
Dilated cardiomyopathy (DCM)	182	Higher stages of hypertension	220
Hypertrophic cardiomyopathy (HCM)	185	Treatment in an acute setting	221
Restrictive cardiomyopathy	186	Self-assessment questions	223
Other cardiomyopathies	186	Chapter 9	
Cardiac arrhythmias	187	NEPHROLOGY	225
Sinus node disturbances	187	<i>Annemarie Hennessy and Randall Faull</i>	
Sick sinus syndrome	187	Inherited cystic kidney disease	226
Supraventricular premature complexes (ectopics)	188	Autosomal dominant polycystic kidney disease (ADPKD)	226
Supraventricular tachycardia (SVT)	188	Medullary sponge kidney (MSK)	228
Atrial flutter	189	Medullary cystic disease and autosomal recessive polycystic disease	228
Atrial fibrillation (AF)	190	Acquired kidney cystic disease	229
Ventricular arrhythmias	194	Simple renal cysts	229
		Renal stones/kidney stones	229

Kidney and urinary tract infection	232	The kidneys in pregnancy and pregnancy-related diseases	257
Mechanisms of disease	232	Normal adaptations to pregnancy	257
Clinical presentation, investigation and diagnosis	232	Underlying renal disease	257
Treatment and targets for urinary tract infection	233	Self-assessment questions	259
Inherited renal basement membrane disease	233	Chapter 10	
Thin basement membrane disease	233	ENDOCRINOLOGY	261
Alport syndrome	233	<i>David Simmons, Rohit Rajagopal, Milan K Piya, Sue Lynn Lau and Mark McLean</i>	
Glomerulonephritis (GN)	233	System overview	262
Classification	233	Hormones, their transport and action	262
Primary glomerular inflammatory disease	234	Feedback control of hormone systems	262
Secondary glomerular inflammatory disease	240	Evaluating function of hormone systems	263
Sclerosing glomerular disease	242	Pathogenic mechanisms of hormone disorders	263
Diabetes mellitus	242	Disorders of the pituitary and hypothalamus	264
Focal sclerosing glomerular nephropathy (FSGN)	243	Anatomy and physiology	264
Vascular renal disease	244	Pituitary mass lesions	265
Renal artery stenosis	244	Hypopituitarism	266
Treatment of renovascular disease	245	Syndromes of hypersecretion	267
Thrombotic thrombocytopenic purpura (TTP)/ Hemolytic uremic syndrome (HUS)	245	Surgery and radiotherapy for pituitary tumors	268
Malignant hypertension	246	Inflammatory and infiltrative disorders	268
Mechanisms of renal injury in hypertension	246	Diabetes insipidus (DI)	269
Clinical presentation, investigation and diagnosis	246	Thyroid disorders	269
Treatment and targets	246	Physiology and assessment of thyroid function	269
Scleroderma kidney	247	Thyroid imaging	269
Mechanisms of scleroderma kidney and renal crisis	247	Thyroid autoimmunity	270
Clinical presentation, investigation and diagnosis	247	Hyperthyroidism	270
Treatment and targets for scleroderma	247	Hypothyroidism	272
Reflux nephropathy	247	Goiter and thyroid nodules	274
Clinical presentation, investigation and diagnosis	247	Thyroid cancer	274
Treatment and targets	248	Thyroid in pregnancy	275
Chronic kidney disease (CKD)	248	Disorders of bone and mineral metabolism	275
Classification systems and definitions	248	Mineral homeostasis	275
Early stages of CKD	248	Hypercalcemia	275
Clinical presentations of stage 3 CKD	249	Hypocalcemia	278
Clinical presentations of stages 4 and 5 CKD	249	Osteoporosis	279
End-stage renal disease (ESRD) and renal replacement therapy	249	Osteomalacia and rickets	280
Acute renal failure—acute kidney injury (AKI)	252	Vitamin D deficiency	280
Tubulo-interstitial diseases	252	Paget's disease (PD)	281
Acute interstitial nephritis (AIN)	252	Adrenal disorders	282
Chronic tubulo-interstitial disease	253	Physiology and assessment of adrenal function	282
Electrolyte disorders	253	Adrenal insufficiency	282
Hypernatremia	253	Cortisol excess (Cushing's syndrome)	284
Hyponatremia	254	Primary hyperaldosteronism (Conn's syndrome)	285
Hyperkalemia	254	Pheochromocytoma	286
Hypokalemia	255	Congenital adrenal hyperplasia (CAH)	287
Inherited 'channelopathies' associated with hypertension or HYPO/hyperkalemia	256	Incidentally found adrenal masses ('incidentaloma')	289
Hypokalemic alkalosis (with and without hypertension)	256	Growth and puberty	289
Renal tubular acidosis	256	Causes of short stature	289
		Onset of puberty—physiology	289
		Causes of delayed puberty	290
		Common causes of precocious puberty	290

Male reproductive endocrinology	292	Eosinophilic gastroenteritis (EGE)	335
Testicular function	292	Chronic idiopathic intestinal pseudo-	
Male hypogonadism	292	obstruction (CIIP)	336
Causes of erectile dysfunction	293	Short bowel syndrome	336
Gynecomastia	293	Nutritional deficiency	336
Androgen replacement therapy	293	Clinical clues to malnutrition	336
Female reproductive endocrinology	293	Nutritional assessment in end-stage liver	
Anatomy and physiology	293	disease	336
Clinical and laboratory evaluation	294	Enteral and parenteral nutrition	340
Hirsutism and hyperandrogenism	295	Large bowel	341
Polycystic ovary syndrome (PCOS)	295	Irritable bowel syndrome (IBS)	341
Female hypogonadism	295	Constipation	341
Endocrinology of pregnancy	296	Diverticular disease	343
Neuroendocrine tumors (NETs)	296	Inflammatory bowel disease (IBD)	343
Overview	296	Colon polyps	350
Carcinoid syndrome	297	Colon cancer screening	350
Glucagonoma	297	Recommendations for screening and	
VIPoma	297	surveillance	350
Insulinoma	297	Fecal occult blood testing (FOBT)	352
Treatment of malignant NETS	298	Malignant potential and surveillance	352
Disorders of multiple endocrine systems	298	Gastrointestinal bleeding	354
Multiple endocrine neoplasia (MEN)	298	Upper	354
Other multiple endocrine tumor		Lower	355
syndromes	299	Obscure GI bleeding	356
Polyglandular autoimmunity (PGA)		Management of iron-deficiency anemia	357
syndromes	299	Pancreas	357
Diabetes and metabolism	299	Acute pancreatitis	357
Overview of energy metabolism	299	Chronic pancreatitis	360
Carbohydrate metabolism and diabetes	300	Autoimmune pancreatitis (AIP)	361
Disorders of energy excess—overweight and		Pancreatic cysts	362
obesity	309	Acknowledgments	362
The metabolic syndrome	311	Self-assessment questions	363
Self-assessment questions	312		
Chapter 11		Chapter 12	
GASTROENTEROLOGY	317	HEPATOLOGY	369
<i>Magnus Halland, Michael Potter, Georgia Edwards,</i>		<i>Robert Gibson, Magnus Halland and</i>	
<i>Vimalan Ambikaipaker and Nicholas J Talley</i>		<i>Nicholas J Talley</i>	
Esophagus	318	Liver function tests and their abnormalities	370
Dysphagia	318	Serum enzymes	370
Motor disorders	318	Tests of synthetic function	370
Esophagitis due to causes other than acid		Noninvasive hepatic fibrosis assessment	370
reflux	320	Approach to the patient with liver disease	370
Stomach	321	Bilirubin metabolism and jaundice	372
Physiology of acid secretion	321	Viral hepatitis	375
Dyspepsia and its management	322	Hepatitis A (RNA virus)	375
Gastritis and gastropathy	323	Hepatitis B (DNA virus)	376
Peptic ulcer disease (PUD)	323	Hepatitis C (RNA virus)	379
Tumors	324	Hepatitis D, E and G	380
Post-gastrectomy complications	324	Other viruses causing hepatitis	381
Gastroparesis	325	Noninvasive assessment of liver fibrosis	381
Small bowel	325	Cirrhosis	381
Celiac disease	325	Useful investigations	382
Diarrhea	326	Prognosis	382
Malabsorption	333	Management	382
Microscopic colitis	334	Ascites	383
Tropical sprue	334	Management	383
Small intestinal bacterial overgrowth		Hepatorenal syndrome (HRS)	385
(SIBO)	335	Management	386
		Hyponatremia	386

Spontaneous bacterial peritonitis (SBP)	386	Von Willebrand disease (vWD)	412
<i>Treatment</i>	386	Hemophilia A	414
Portal hypertensive bleeding	387	Hemophilia B	415
<i>Management</i>	387	Bleeding disorders due to deficiencies of other coagulation factors	415
Portosystemic encephalopathy (PSE)	388	Platelet disorders	415
<i>Precipitant-induced PSE</i>	389	<i>Idiopathic thrombocytopenic purpura (ITP)</i>	415
<i>Persistent PSE</i>	389	<i>Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome</i>	416
<i>Minimal encephalopathy</i>	389	Disseminated intravascular coagulation (DIC)	417
Portopulmonary hypertension (POPH)	390	<i>Diagnosis</i>	418
Hepatopulmonary syndrome (HPS)	390	<i>Treatment</i>	418
Cirrhotic cardiomyopathy	390	Coagulopathy in intensive care patients	419
Acute liver failure (ALF)	391	Myeloproliferative disorders	419
Liver transplantation	391	<i>Polycythemia vera (PV)</i>	419
Drugs and the liver	392	<i>Essential thrombocythemia (ET)</i>	421
<i>Acetaminophen (paracetamol) and acute liver disease</i>	392	<i>Primary myelofibrosis (PMF)</i>	423
Alcohol and the liver	394	Leukemia	424
Specific liver diseases	394	<i>Acute myeloid leukemia (AML)</i>	424
<i>Budd–Chiari syndrome (BCS)</i>	394	<i>Acute promyelocytic leukemia (APML)</i>	426
<i>Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)</i>	395	<i>Acute lymphoblastic leukemia (ALL)</i>	427
<i>Wilson's disease (hepatolenticular degeneration)</i>	396	<i>Myelodysplastic syndrome (MDS)</i>	427
<i>Alpha-1 anti-trypsin deficiency</i>	396	<i>Chronic myeloid leukemia (CML)</i>	428
<i>Hemochromatosis</i>	396	<i>Chronic lymphocytic leukemia and other B-cell disorders</i>	430
Autoimmune liver diseases	397	Non-Hodgkin lymphomas	432
<i>Autoimmune hepatitis (AIH)</i>	397	<i>Diagnosis</i>	432
<i>Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC)</i>	397	<i>Staging</i>	432
Systemic disease and the liver	398	<i>Diffuse large B-cell lymphoma (DLBCL)</i>	432
Pregnancy and liver disease	398	<i>'Cell of origin' classification of DLBCL</i>	433
Gallbladder and biliary tree	398	<i>'Double-hit' (DH) and 'triple-hit' (TH) lymphomas</i>	433
<i>Gallstones</i>	399	<i>Burkitt lymphoma</i>	433
<i>Acalculous cholecystitis</i>	400	<i>Follicular lymphoma (FL)</i>	433
Porphyrias	400	<i>Mantle cell lymphoma (MCL)</i>	434
<i>Acute intermittent porphyria (AIP)</i>	400	<i>Cutaneous lymphomas</i>	434
<i>Porphyria cutanea tarda (PCT)</i>	400	Hodgkin lymphoma (HL)	435
Self-assessment questions	401	<i>Histological subtypes and cell biology</i>	435
Chapter 13		<i>Staging</i>	435
HEMATOLOGY	405	<i>Risk stratification</i>	435
<i>Stephen James Fuller</i>		Plasma cell disorders	436
Hemostasis	406	<i>Monoclonal gammopathy of uncertain significance (MGUS)</i>	436
<i>Essential concepts</i>	406	<i>Asymptomatic myeloma</i>	436
<i>Components of the hemostatic system</i>	406	<i>Symptomatic myeloma</i>	436
Venous thrombosis	408	<i>Prognostic markers in myeloma</i>	437
<i>Predisposition to venous thrombosis</i>	408	<i>Treatment of myeloma</i>	437
<i>Diagnosis of venous thrombosis</i>	409	<i>Differential diagnosis</i>	437
<i>Treatment of venous thromboembolism (VTE)</i>	410	Anemia	438
<i>Post-thrombotic syndrome (PTS)</i>	410	<i>Mechanisms of anemia</i>	438
Antiphospholipid syndrome (APS)	410	<i>Common laboratory tests used for diagnostic work-up</i>	438
<i>Treatment</i>	411	<i>Approach to iron-deficiency anemia</i>	440
Thrombosis at unusual sites	411	<i>Management of iron deficiency</i>	440
<i>Cerebral vein thrombosis (CVT)</i>	411	<i>Anemia of chronic disease</i>	440
<i>Portal vein thrombosis (PVT)</i>	411	<i>Thalassemias</i>	440
Cancer and thrombosis	411	<i>Sideroblastic anemias</i>	441
Bleeding disorders	412	<i>Macrocytic anemias</i>	441
		<i>Hemolytic anemias</i>	443
		<i>Drug-induced hemolysis</i>	448

Non-immune acquired hemolytic anemias (DAT negative)	448	Paraneoplastic syndrome	468
Acknowledgment	448	Cancer with unknown primary (CUP)	468
Self-assessment questions	449	Diagnosis	468
		Potentially treatable subgroups of CUP	468
		Recent research and future directions	469
Chapter 14		Lung cancer	469
ONCOLOGY	457	Clinical presentation	469
<i>Victoria Bray, Wei Chua, Christos S Karapetis and Melissa Moore</i>		Risk factors	469
What is cancer?	459	Epidemiology and pathology	469
DNA and genes	459	Non-small-cell lung cancer (NSCLC)	469
Basic elements of cancer biology	459	Molecular profiling	469
Essential elements of cancer diagnosis and treatment	459	Prognosis	469
Prevention	459	Management	469
Diagnosis	460	Treatment of stage IV NSCLC	470
Screening	460	Small cell lung cancer (SCLC)	471
Signs and symptoms	460	Renal cancer	471
Diagnostic tests	460	Background	471
Prognosis	461	Diagnosis and staging	471
Cancer factors	461	Treatment	472
Patient factors	461	Prognosis	472
Prognostic vs predictive factors	461	Tumors of the pelvis, ureter and bladder	472
Treatment principles	461	Epidemiology	472
Defining treatment goals	461	Risk factors	472
Adjuvant therapy	462	Clinical presentation	473
Neoadjuvant therapy	462	Investigation and diagnosis	473
Supportive management	462	Treatment	473
Maintenance therapy	462	Prostate cancer	473
Principles of chemotherapy	462	Epidemiology	473
Attitudes to chemotherapy	463	Screening	473
Toxicity of cytotoxic chemotherapy	463	Staging	473
Principles of radiotherapy	463	Management	473
Fractionation	464	Testis cancer	474
Radiation effects	464	Epidemiology and risk	474
Treatment responsiveness	464	Pathology	474
Endocrine responsive	464	Diagnosis	474
Potentially curable following chemotherapy alone	464	Prognostic factors in stage I NSGCT	475
Tumors very sensitive to chemotherapy	464	Treatment	475
Potentially curable following radiotherapy	464	Post-chemotherapy residual masses	475
Personalized medicine	464	Relapsed disease	476
Molecular targeted therapy	464	High-dose chemotherapy (HDCT)	476
Monoclonal antibodies (the 'ABs')	464	Head and neck cancer	476
Tyrosine kinase inhibitors (the 'IBs')	465	Early-stage disease	476
Other	465	Advanced-stage disease	476
Familial cancers and cancer genetics	465	Human papillomavirus (HPV) infection	476
Oncological emergencies	465	Esophageal cancer	476
Spinal cord compression	465	Pathology and epidemiology	476
Febrile neutropenia	466	Clinical presentation	476
Cardiac tamponade	466	Diagnosis and screening	477
Addisonian crisis	467	Management	477
Disseminated intravascular coagulation (DIC)	467	Gastric cancer	477
Hypercalcemia	467	Epidemiology	477
Hyponatremia	467	Clinical presentation	477
Superior vena cava (SVC) obstruction	467	Diagnosis	477
Raised intracranial pressure (ICP)	467	Treatment	477
Tumor markers in serum	467	Gastric MALT lymphoma	478
		Colorectal cancer	478
		Pathology and epidemiology	478
		Diagnosis and staging	478
		Management	479
		Future directions	480

Pancreatic cancer	480	Pathophysiological basis	496
Key points	480	Interventions	496
Epidemiology	480	Fatigue	497
Diagnosis	480	Definition	497
Management	480	Impact of the problem	497
Hepatocellular carcinoma (HCC)	481	Pathophysiological basis	497
Key points	481	Interventions to palliate the problem	497
Risk factors	481	Nausea and vomiting	497
Prognosis	481	Definition	497
Treatment	481	Impact of the problem	498
Brain tumors	482	Pathophysiological basis	498
Low-grade glioma (astrocytoma and oligodendroglioma)	482	Interventions to palliate the problem	498
Glioblastoma multiforme (GBM)	482	Cachexia and anorexia	500
Lymphoma	482	Definition	500
Melanoma	483	Impact of the problems	500
Pathology and epidemiology	483	Underlying pathophysiological basis	500
Diagnosis and staging	483	Interventions	501
Management	483	Breathlessness	501
Advanced disease	483	Definition	501
Non-melanoma skin cancer	483	Impact of the problem	501
Risk factors	483	Pathophysiological basis	501
Management	484	Interventions to palliate the problem	502
Sarcoma	484	Constipation	502
Clinical presentation	484	Definition	502
Diagnosis	484	Impact of the problem	502
Treatment	484	Pathophysiological basis	502
Breast cancer	485	Interventions to palliate the problem	502
Epidemiology	485	Delirium	502
Risk factors	485	Definition	502
Pathology	485	Impact of the problem	502
Screening	485	Pathophysiological basis	503
Diagnosis and staging	485	Interventions to palliate the problem	503
Management	485	Insomnia	503
Recent research and future directions	487	Definition	503
Ovarian cancer	487	Impact of the problem	503
Key points	487	Pathophysiological basis	503
Pathology and epidemiology	487	Interventions to palliate the problem	504
Diagnosis	488	Self-assessment questions	505
Management	488	Chapter 16	
Future directions	488	IMMUNOLOGY	507
Endometrial cancer	488	<i>Brad Frankum, Monique Wei Meng Lee and Jessie A Lee</i>	
Pathology and epidemiology	488	Key concepts in immunobiology	508
Diagnosis	488	Innate and adaptive immunity	508
Management	489	Specificity and diversity	509
Cancer survivorship	489	Immunological memory	510
Self-assessment questions	490	Hypersensitivity, autoimmunity and immunodeficiency	511
Chapter 15		Immunity, inflammation and tissue repair	511
PALLIATIVE MEDICINE	493	Understanding immunobiology	512
<i>Meera Agar, Katherine Clark and David Currow</i>		Manipulation of the immune system	512
Pain	494	Allergic disease	513
Definition	494	Anaphylaxis	513
Impact of the problem	494	Allergic rhinitis (AR) and allergic conjunctivitis (AC)	514
Pathophysiological basis	494	Chronic rhinosinusitis	516
Interventions to palliate the problem	494	Atopic dermatitis (AD)	518
Mucositis	496		
Definition	496		
Impact of the problem	496		

Food allergy	519	Psoriatic arthritis (PsA)	573
Urticaria and angioedema	521	Reactive arthritis (ReA)	574
Drug allergy	524	IBD-associated spondyloarthropathy	575
Insect venom allergy	525	Adult-onset Still's disease (AOSD)	575
Eosinophilia	526	Crystal arthropathies	575
Hypereosinophilic syndrome (HES)	526	Gout	575
Mast cell disorders	527	Pseudogout	579
Cutaneous mastocytosis (CM)	527	Relapsing polychondritis (RP)	580
Systemic mastocytosis (SM)	527	Osteoarthritis (OA)	580
Systemic autoimmune disease	528	Types of osteoarthritis	581
Systemic lupus erythematosus (SLE)	528	Clinical features	581
Sjögren's syndrome (SS)	532	Specific joint involvement	581
Inflammatory myopathies	535	Investigations	582
Anti-synthetase syndrome	535	Treatment	582
Scleroderma and CREST syndrome	537	Genetic connective tissue disorders	584
Mixed connective tissue disease (MCTD)	538	Painful shoulders	584
Antiphospholipid syndrome (APS)	539	Clinical assessment	585
IgG4-related disease	539	Examination	585
Primary vasculitis	540	Rotator cuff disease	585
Large-vessel vasculitis	540	Frozen shoulder/adhesive capsulitis	586
Medium-vessel vasculitis	542	Tennis elbow and golfer's elbow	587
Small-vessel vasculitis	543	Tennis elbow (lateral epicondylitis)	587
Single-organ vasculitis	545	Golfer's elbow (medial epicondylitis)	587
Variable-vessel vasculitis	545	Plantar fasciitis	588
Autoinflammatory disorders	546	Fibromyalgia	588
Familial Mediterranean fever (FMF)	546	Epidemiology and etiology	589
TNF-receptor-associated periodic syndrome (TRAPS)	547	Investigations	589
Immunodeficiency	547	Prognosis, differential diagnosis and treatment	590
Primary immunodeficiency	547	Septic arthritis	590
Secondary (acquired) immunodeficiency	550	Investigations	591
HIV/AIDS	550	Treatment	591
Epidemiology	551	Acute low back pain	591
Risk factors for HIV infection	551	Specific pathology leading to acute low back pain	592
Pathophysiology	551	Management	593
Clinical features and diagnosis	552	Outcome	593
Management	553	Chronic low back pain	594
Prognosis	555	Clinical assessment	594
Self-assessment questions	557	Conservative treatment	594
		Invasive treatment	594
		Self-assessment questions	595
Chapter 17		Chapter 18	
MUSCULOSKELETAL MEDICINE	563	NEUROLOGY	599
<i>Carlos El Haddad and Kevin Pile</i>		<i>Christopher Levi and Thomas Wellings</i>	
An approach to a patient with painful joints	564	Disorders of consciousness	600
History	564	Definitions	600
Examination	565	Levels of consciousness	600
Investigations	566	Causes of coma	600
Rheumatoid arthritis (RA)	566	Assessment of the patient with impaired consciousness	601
Genetics and environmental contribution to RA	566	Headache	602
Pathology	567	Primary headache syndromes	602
Diagnosis	567	Secondary headache	606
Clinical features and complications	567	Stroke	608
Investigations	569	Acute assessment and management	608
Treatment	569	Thrombolysis	609
Conclusions	571	Neurosurgical intervention	610
Spondyloarthropathies	571		
Ankylosing spondylitis (AS)	572		

General care measures	611	Genetic disorders	644
Early secondary prevention	611	Neuromuscular disorders	645
Intracerebral hemorrhage	612	Myasthenia gravis (MG)	645
Medical treatment	612	Disorders of peripheral nerves	647
Surgical management	612	Motor neuron disease (MND)/amyotrophic lateral sclerosis	647
Subarachnoid hemorrhage (SAH)	612	Demyelinating neuropathy and Guillain-Barré syndrome (GBS)	649
Natural history and outcome of an aneurysmal SAH	612	Peripheral neuropathy	650
Surgical versus endovascular management of SAH	612	Self-assessment questions	652
Transient ischemic attack (TIA)	613	Chapter 19	
Definition	613	PSYCHIATRY FOR THE INTERNIST	657
Differential diagnosis of transient neurological disturbances	613	<i>Brian Kelly and Lisa Lampe</i>	
Pathophysiology	613	Depression	657
Investigation	613	Anxiety disorders	658
Recurrent event risk	613	Treatment	659
Prevention of recurrent events	613	Post-traumatic stress disorder (PTSD)	659
Dementia	614	Somatization	659
Diagnosis	614	Eating disorders	660
Major dementia syndromes	614	Anorexia and bulimia nervosa	661
Diagnostic work-up of the dementia patient	615	Suicide and deliberate self-harm	661
Other dementia syndromes	615	Psychotropic agents	662
Seizures and the epilepsies	617	Lithium carbonate	662
Seizure types	617	Anticonvulsants	662
Assessing a patient after a seizure	618	Antipsychotic agents	663
Investigation of a first seizure	619	Antidepressants	664
The epilepsies	619	Self-assessment questions	665
Important epilepsy syndromes	619	Chapter 20	
Choice of anticonvulsant therapy	622	CLINICAL INFECTIOUS DISEASES	667
Status epilepticus	622	<i>Iain Gosbell and D Ashley R Watson</i>	
Non-epileptic seizures	624	Clinical approach to infectious diseases	668
Balance, dizziness and vertigo	624	Overview	668
Hemodynamic dizziness or 'lightheadedness'	625	History	668
Vertigo	625	Examination	668
Central pathologies	627	Diagnostics in infectious diseases	669
Treatment of vertiginous patients	628	Pre-analytical considerations	669
Other balance disorders	629	Analytical considerations	669
Movement disorders	629	Post-analytical considerations	669
Tremor	629	Selected common clinically important organisms	670
Parkinson's disease (PD)	630	Selected bacteria	670
Dementia with Lewy bodies (DLB)	633	Selected viruses	672
Multisystem atrophy (MSA)	633	Selected fungi	674
Progressive supranuclear palsy (PSP)	633	Selected parasites	677
Corticobasal syndrome	633	Anti-infective treatment	677
Dystonia	633	Is infection likely?	677
Hyperkinetic movement disorders	634	What are the likely pathogen(s)?	678
NMDA encephalitis	635	Are anti-infective drugs required?	679
Multiple sclerosis and CNS inflammation	636	Choice of empirical and definitive antibiotics	679
Multiple sclerosis (MS)	636	What host factors need consideration?	679
Neuromyelitis optica (NMO; 'Devic's disease')	640	What therapy other than antibiotics is required?	679
Acute disseminated encephalomyelitis (ADEM) and transverse myelitis (TM)	640	Ongoing assessment and further results	679
Neurological manifestations of sarcoidosis and Behçet's disease	641	What is the duration and endpoint of treatment?	679
Sarcoidosis	641	Anti-infective agents	680
Behçet's disease	641	Antibiotics	680
Neuromuscular disease	641		
Myopathy	642		

Antiviral agents	687
Antifungals	688
Specific syndromes	690
Acute fever	690
Pyrexia of unknown origin (PUO)	690
Skin and soft tissue infections	692
Drug fever	694
Infections in special hosts and populations	695
Infections in immunosuppressed patients	695
Sexually transmitted infections (STIs)	696
Systemic viral infections	702
HIV	702
Hepatitis viruses	702
Herpesviruses	702
Zoonoses	703
Infection prevention and control	706
Administrative support	706
Judicious use of antibiotics	707
MRO surveillance	707
Infection control precautions	707
Environmental measures	707
Decolonization	707
Self-assessment questions	708

Chapter 21 IMMUNIZATION 711

<i>Robert W Pickles</i>	
General principles	711
Immunizing agents	712
Factors affecting immunogenicity	714
Chemical and physical properties of antigens (vaccines)	714
Physiological attributes of individuals	714
Route of administration	714
Presence of adjuvants	714
Contraindications	714
False contraindications	714
Egg allergy	714
Booster doses	714
Immunization in specific populations	714
Pregnancy	714
Preconception	715
Breastfeeding	715
Immunocompromised hosts	715
Oncology patients	719
Solid-organ transplant patients	719
Hemopoietic stem-cell transplant (HSCT) recipients	719
HIV/AIDS	719
Asplenia	719
Occupational exposure	719
Travel vaccines	719
Post-exposure prophylaxis (PEP)	719
Intramuscular immune globulin	719
Specific intramuscular immune globulin preparations (hyperimmune globulins)	719
Specific immune globulins for intravenous use	721
Routine immunization of adults	721
Self-assessment questions	722

Chapter 22 DERMATOLOGY FOR THE PHYSICIAN 727

<i>Brad Frankum and Saxon D Smith</i>	
Autoinflammatory diseases of the skin	727
Acne	727
Atopic dermatitis	728
Hidradenitis suppurativa	728
Psoriasis	729
Erythema nodosum (EN)	729
Bullous lesions	730
Dermatitis herpetiformis	731
Livedo reticularis	732
Skin problems associated with underlying systemic disease	732
Acanthosis nigricans	732
Neutrophilic dermatoses	733
Pruritus	734
Pigmentation	734
Photosensitivity	734
Rash on the palms and soles	734
Red person syndrome (erythroderma or exfoliative dermatitis)	734
Excessive sweating (hyperhidrosis)	735
Facial flushing	735
Genetic or congenital skin diseases	735
The phakomatoses	735
Skin disease associated with malignancy	736
Primary or secondary malignancy	736
Underlying malignancy	737
Self-assessment questions	738

Chapter 23 MEDICAL OPHTHALMOLOGY 739

<i>Michael Hennessy, Brad Frankum, Peter McCluskey and Elisa Cornish</i>	
Introduction	739
Ocular history	740
Ocular examination	740
General inspection findings	740
Visual acuity	740
Intraocular pressure	740
Field of vision	741
Pupils	741
Color saturation	742
Ocular motility	742
Ophthalmoscopy	743
Auscultation	743
Ocular conditions	744
Retinal vascular disease	744
Retinal arterial occlusion	744
Retinal venous occlusion	745
Diabetic retinopathy (DR)	746
Uveitis	747
Scleritis	747
Thyroid-related orbitopathy	747
Dry eye	748
Neoplasia and the eye	748
Neuro-ophthalmology	749

Optic neuritis (ON)	749
Non-arteritic anterior ischemic optic neuropathy (NAION)	749
Arteritic anterior ischemic optic neuropathy (AAION)	749
Papilledema	750
Extraocular muscle paralysis	750
Phakomatoses	750
Ocular effects of systemic medication	750
Self-assessment questions	752

Chapter 24 WOMEN'S HEALTH FOR THE PHYSICIAN 755

Steve Robson and Andrew Korda

Infertility	755
Age and infertility	756
Anovulatory infertility	756
Hyperprolactinemia	757
Infertility due to anatomical abnormalities of the reproductive tract	757
Male factor infertility	757
Unexplained infertility	757
Contraception	757
Steroidal contraception	758
Emergency contraception	760
Menopausal symptoms	760
Premenstrual syndrome	761
Abnormal uterine bleeding	761
Diagnosis	761
Management	762
Dysmenorrhea	762
Vulvar conditions	762
Management	762
Conditions with abnormalities on examination	763
Sexually transmitted infections (STIs)	765
Chlamydia	765
Gonorrhea	766
Pelvic inflammatory disease (PID)	766
Clinical features	766
Treatment	767
Sexual problems	767
Treatment	768
Self-assessment questions	769

Chapter 25 OBSTETRIC MEDICINE 771

Annemarie Hennessy and Angela Makris

General principles of medical obstetric care	772
Diabetes in pregnancy	772
Gestational diabetes	773
Type 1 diabetes in pregnancy	774
Type 2 diabetes in pregnancy	774
Hypertension in pregnancy	775
Mechanisms of disease	775
Clinical presentation, investigation and diagnosis	775

Treatment and targets	776
Prevention strategies for preeclampsia	776
Respiratory disease in pregnancy	777
Pneumonia	777
Asthma	777
Venous thromboembolism (VTE) in pregnancy	778
Thyroid disorders in pregnancy	778
Hypothyroidism	779
Hyperthyroidism	779
Common gastroenterological and liver disorders in pregnancy	779
Gastroesophageal reflux disease (GERD)	779
Constipation and irritable bowel syndrome (IBS)	779
Inflammatory bowel disease (IBD)	780
Cholestasis of pregnancy	780
Acute fatty liver of pregnancy (AFLP)	781
Budd–Chiari syndrome in pregnancy	781
Viral infection in pregnancy	781
Viral hepatitis	781
Immunological and hematological disease in pregnancy	782
Systemic lupus erythematosus (SLE)	782
Antiphospholipid syndrome (APS)	782
Idiopathic thrombocytopenic purpura (ITP)	783
Iron-deficiency anemia (IDA)	783
Cardiac disease in pregnancy	783
Valvular heart disease	783
Arrhythmias and palpitations	784
Cardiomyopathy, including postpartum cardiomyopathy	784
Other vascular conditions	784
Obesity in pregnancy	785
Neurological conditions in pregnancy	785
Self-assessment questions	786

Chapter 26 GERIATRIC MEDICINE 789

Will Browne, Balakrishnan Kichu R Nair, Elizabeth Whiting, Jeffrey Rowland, Paven Preet Kaur and Ramdeep Bajwa

Introduction	790
Epidemiology of aging	790
Theories of aging	790
Processes underlying aging	790
Homeostenosis	790
Evolution and aging	790
Telomere shortening and mitochondrial dysfunction	790
Endocrine factors associated with aging	790
Inflammation and aging	791
Free radicals and aging	791
Programmed aging	791
Physiology of aging	791
Cardiovascular changes	791
Cardiac changes	791
Renal changes	791
Musculoskeletal changes	791
Neurological changes	792

<i>Skin changes</i>	792	Special considerations	798
<i>Metabolic and endocrine changes</i>	792	<i>Undernutrition</i>	798
<i>Gastrointestinal changes</i>	792	<i>Advance care planning</i>	798
Pathology: disease in older people	792	<i>Capacity</i>	798
<i>Concepts related to aging</i>	792	<i>End of life care</i>	799
<i>Common problems typical to older people</i>	793	<i>Immunizations</i>	799
Atypical presentation of acute illness	796	<i>Elder abuse</i>	799
<i>Delirium</i>	796	Treatment considerations	799
<i>Declining mobility and falls</i>	796	<i>Polypharmacy</i>	799
<i>New incontinence</i>	796	<i>Bed rest</i>	799
Geriatrics, the 5M's and the role of the		<i>Futility of treatment</i>	799
Geriatrician	797	Self-assessment questions	800
Approach to comprehensive geriatric			
assessment	797	Index	807